ARCHIVES

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

DeVita Losing Patience, Responds To Powers Letter

May 6, 1983

Intramural Clinical Research Could Lose “Critical Mass” – Chabner

November 11, 1994

Group Chairs Seek Role Running NCTN

September 12, 2014

In Brief: ONS Forms Six New Special Interest Groups; Four Named To Michigan Breast Cancer Center

April 13, 1990

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

UC Davis Cancer Center Wins NCI Designation

July 19, 2002